Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

NCT01913405 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

BIOLOGICAL: PEGylated Recombinant factor VIII (rFVIII)

Sponsor

Baxalta now part of Shire